FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal …
FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal …
Amgen today announced that the U.S. Food and Drug Administration has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events in patients with cancer.
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Risks Tags: application, Biologics, Denosumab, Designation, Grants, License, priority, reduction, Review, Skeletal